FDA approves new drug Zynyz for two rare and aggressive types of cancer.

The U.S. Food and Drug Administration (FDA) has approved a new medicine called Zynyz. It is a type of immunotherapy, which works by helping the body's own immune system fight cancer. It is specifically for adults with two rare and aggressive cancers: advanced squamous cell carcinoma of the anal canal and Merkel cell carcinoma, a type of skin cancer. For anal cancer, it can be used either as a first treatment with other chemotherapy drugs or by itself if other treatments have stopped working. For Merkel cell carcinoma, it is used by itself for cancer that has spread or returned. This approval means doctors now have another tool to consider for patients facing these difficult cancers. It is given as an intravenous (IV) infusion every four weeks. It's important to know that this is a new approval based on clinical studies. As with any treatment, it may not work for everyone and can have side effects. The most important step for anyone interested in this new option is to have a detailed conversation with their own healthcare team. They can provide personalized information about whether Zynyz is a suitable choice based on an individual's specific health situation.